High dose epirubicin versus mitoxantrone in a seven-drug combination regimen for intermediate and high grade NHL: results of a randomized pilot study

The aim of the present pilot study was an attempt to improve the therapeutic outcome of this group of patients by increasing the dose of the most active drug i.e. anthracycline, through the use of high dose Epirubicin and compare it with the standard regimen in common use in the institution. Also, this work aimed at studying the safety of increasing the Epirubicin dose especially in terms of hematological [BM] and cardiotoxicity